Shots:

• The BTD is based on P-I/II MM1636 study assessing IO102-IO103 (q2w- until 12wks. and thereafter q4w up to 1yr.) in combination with anti-PD-1 Ab- as a 1L treatment for metastatic melanoma
• The combination of IO102 and IO103 vaccines and nivolumab demonstrated encouraging early efficacy data; ORR (79%) was reached with CR (45%) or complete disappearance of their tumors
• IO102 and IO103 are first-in-class- immune modulatory vaccines designed to engage and activate IDO and PD-L1 specific human T-cells

 ­ Ref: PRNewswire | Image: PRNewswire